MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-24-2026
BioCardia Total Shareholders Equity 2011-2026 | BCDA
Annual Total Shareholders Equity BioCardia
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 895 K | 837 K | -1.6 M | 4.89 M | 10.4 M | 19.2 M | 2.37 M | 3.79 M | 11.1 M | 20.6 M | -3.44 M | -43.1 K | 13.5 M | 13.3 M | 13 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 M | -3.44 M | 7.25 M |
Quarterly Total Shareholders Equity BioCardia
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.63 M | -1.89 M | -1.52 M | 837 K | 2.75 M | -1.96 M | -2.28 M | -1.6 M | -660 K | 1.64 M | 1.9 M | 4.89 M | 4.1 M | 6.73 K | 7.37 M | 10.4 M | 13.4 M | 15.7 M | 18.6 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 2.37 M | 2.37 M | 2.37 M | 2.37 M | 3.79 M | 3.79 M | 3.79 M | 3.79 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | -3.44 M | 13.9 M | 13.9 M | 13.9 M | -43.1 M | 13.5 M | 13.5 M | 13.6 M | 13.3 M | 13.5 M | 13.4 M | 13.4 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13 M | 13 M | 13 M | 13 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 M | -43.1 M | 8.42 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.8 | 5.33 % | $ 9.14 B |  Australia |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.63 | -1.22 % | $ 16.5 M | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
1.37 B | $ 88.34 | -3.22 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
28.3 M | $ 3.41 | -3.67 % | $ 230 B | Britain |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 316.2 | -4.28 % | $ 41.4 B | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 4.44 | -0.67 % | $ 730 M | Britain |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.89 | - | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Cerus Corporation
CERS
|
64.2 M | $ 1.8 | -2.7 % | $ 343 M | USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 202.28 | -2.11 % | $ 358 B | USA |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.04 | -1.28 % | $ 432 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.63 | -2.69 % | $ 191 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.32 | -2.06 % | $ 992 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 8.12 | -1.22 % | $ 222 M |  Israel |
 |
Ardelyx
ARDX
|
167 M | $ 5.8 | -2.93 % | $ 1.4 B | USA |